Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Date: September 19, 2013
Reporting Period: Current event announcement (not a financial period report)
Context: GSK and partner Theravance, Inc. announced a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding the marketing authorization of RELVAR ELLIPTA (fluticasone furoate/vilanterol) for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD) in Europe.
Key Financial Metrics
This filing is a regulatory announcement regarding product development and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Regulatory Milestones
- Regulatory Status: The CHMP issued a positive opinion recommending marketing authorization for RELVAR ELLIPTA in Europe for asthma (adults and adolescents 12+) and COPD (adults with FEV1 <70%).
- Next Steps: A final decision by the European Commission is anticipated in the fourth quarter of 2013. A positive opinion does not guarantee final authorization.
- Global Context: The drug (as BREO ELLIPTA) was approved by the US FDA in May 2013 and Health Canada in July 2013 for COPD. A submission for asthma was filed in Japan in September 2012 and remains under review.
- Clinical Data: The EMA assessment reviewed 11 clinical studies involving 7,851 COPD patients and 16 studies involving 9,326 asthma patients.
Outlook, Risks, and Management Commentary
Management Commentary: GSK's President of Pharmaceuticals R&D, Patrick Vallance, described the opinion as a key milestone following over ten years of research. Theravance CEO Rick E. Winningham highlighted the joint R&D partnership and anticipated further regulatory events in late 2013.
Risks and Safety Contingencies:
- Pneumonia: Increased incidence of pneumonia, including hospitalizations and fatal events, was observed in COPD patients. Higher doses in asthma patients also showed numerically higher pneumonia incidence.
- Contraindications: Not for acute bronchospasm or acute asthma/COPD exacerbations. Contraindicated in patients with hypersensitivity to components.
- Systemic Effects: Potential for Cushing's syndrome, adrenal suppression, bone density loss, and hyperglycemia, particularly at high doses or with long-term use.
- Cardiovascular: Caution advised for patients with severe cardiovascular disease due to potential arrhythmias.
- Forward-Looking Statements: Both GSK and Theravance issued standard disclaimers that actual results may differ materially from projections due to regulatory delays, clinical study outcomes, and manufacturing risks.
Investor Verification Checklist
- Confirm the final marketing authorization decision by the European Commission in Q4 2013.
- Review the specific dosing strengths approved for Europe (92/22 mcg and 184/22 mcg) versus US approvals (100/25 mcg).
- Monitor safety data regarding pneumonia incidence in COPD patients post-launch.
- Verify the status of the asthma indication submission in Japan.
- Assess the commercial impact of the RELVAR/BREO launch on GSK's respiratory portfolio relative to competitors.